Figure 5
From: VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis
VX-166 has a beneficial effect on lymphocyte loss, endotoxin and IL-1β levels in CLP. (a) Thymocyte weight of caecal ligation and puncture (CLP) rats from the single dose 10 days survival study was determined in surviving animals at day 10. VX-166 was dosed at 25 mg/ml (white bar) vs. vehicle control (black bar); *P < 0.01. (b) Lymphocyte apoptosis was determined 20 hours post CLP (n = 10 per group) in VX-166-treated (25 mg/ml, white bars) vs. vehicle treated CLP rats (black bar) and sham controls (grey bar); *P < 0.01 vs. vehicle control. (c) Plasma IL-1β levels were determined 20 hours post CLP (n = 10 per group) in VX-166-treated (25 mg/ml, white bars) vs. vehicle treated CLP rats (black bar) and sham controls (grey bar); *P < 0.05 vs. vehicle control. (d) Plasma endotoxin levels were determined 20 hours post CLP (n = 10 per group) in VX-166-treated (25 mg/ml, white bars) vs. vehicle treated CLP rats (black bar) and sham controls (grey bar); *P < 0.05 vs. vehicle control.